These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 34590480)
1. Modeling the Binding and Conformational Energetics of a Targeted Covalent Inhibitor to Bruton's Tyrosine Kinase. Awoonor-Williams E; Rowley CN J Chem Inf Model; 2021 Oct; 61(10):5234-5242. PubMed ID: 34590480 [TBL] [Abstract][Full Text] [Related]
2. Computational Investigation of the Covalent Inhibition Mechanism of Bruton's Tyrosine Kinase by Ibrutinib. Barragan AM; Ghaby K; Pond MP; Roux B J Chem Inf Model; 2024 Apr; 64(8):3488-3502. PubMed ID: 38546820 [TBL] [Abstract][Full Text] [Related]
3. Investigating the Impact of Covalent and Non-covalent Binding Modes of Inhibitors on Bruton's Tyrosine Kinase in the Treatment of B Cell Malignancies - Computational Insights. Issahaku AR; Soliman MES Curr Pharm Biotechnol; 2023; 24(6):814-824. PubMed ID: 35718983 [TBL] [Abstract][Full Text] [Related]
4. Structure-based discovery of novel 4,5,6-trisubstituted pyrimidines as potent covalent Bruton's tyrosine kinase inhibitors. Zou Y; Xiao J; Tu Z; Zhang Y; Yao K; Luo M; Ding K; Zhang Y; Lai Y Bioorg Med Chem Lett; 2016 Jul; 26(13):3052-3059. PubMed ID: 27210433 [TBL] [Abstract][Full Text] [Related]
5. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors. Sharma A; Thelma BK J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362 [TBL] [Abstract][Full Text] [Related]
6. Mechanism of covalent binding of ibrutinib to Bruton's tyrosine kinase revealed by QM/MM calculations. Voice AT; Tresadern G; Twidale RM; van Vlijmen H; Mulholland AJ Chem Sci; 2021 Jan; 12(15):5511-5516. PubMed ID: 33995994 [TBL] [Abstract][Full Text] [Related]
7. Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations. Johnson AR; Kohli PB; Katewa A; Gogol E; Belmont LD; Choy R; Penuel E; Burton L; Eigenbrot C; Yu C; Ortwine DF; Bowman K; Franke Y; Tam C; Estevez A; Mortara K; Wu J; Li H; Lin M; Bergeron P; Crawford JJ; Young WB ACS Chem Biol; 2016 Oct; 11(10):2897-2907. PubMed ID: 27571029 [TBL] [Abstract][Full Text] [Related]
8. Investigating the ibrutinib resistance mechanism of L528W mutation on Bruton's tyrosine kinase via molecular dynamics simulations. Xu B; Liang L; Jiang Y; Zhao Z J Mol Graph Model; 2024 Jan; 126():108623. PubMed ID: 37716293 [TBL] [Abstract][Full Text] [Related]
9. Molecular Insights into the Impact of Mutations on the Binding Affinity of Targeted Covalent Inhibitors of BTK. Awoonor-Williams E; Abu-Saleh AAA J Phys Chem B; 2024 Mar; 128(12):2874-2884. PubMed ID: 38502552 [TBL] [Abstract][Full Text] [Related]
10. Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit. Qiu H; Liu-Bujalski L; Caldwell RD; Follis AV; Gardberg A; Goutopoulos A; Grenningloh R; Head J; Johnson T; Jones R; Mochalkin I; Morandi F; Neagu C; Sherer B Bioorg Med Chem Lett; 2018 Sep; 28(17):2939-2944. PubMed ID: 30122225 [TBL] [Abstract][Full Text] [Related]
13. Structural Complementarity of Bruton's Tyrosine Kinase and Its Inhibitors for Implication in B-Cell Malignancies and Autoimmune Diseases. Najmi A; Thangavel N; Mohanan AT; Qadri M; Albratty M; Ashraf SE; Saleh SF; Nayeem M; Mohan S Pharmaceuticals (Basel); 2023 Mar; 16(3):. PubMed ID: 36986499 [TBL] [Abstract][Full Text] [Related]
14. Predicting the Relative Binding Affinity for Reversible Covalent Inhibitors by Free Energy Perturbation Calculations. Bonatto V; Shamim A; Rocho FDR; Leitão A; Luque FJ; Lameira J; Montanari CA J Chem Inf Model; 2021 Sep; 61(9):4733-4744. PubMed ID: 34460252 [TBL] [Abstract][Full Text] [Related]
15. Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib. Hopper M; Gururaja T; Kinoshita T; Dean JP; Hill RJ; Mongan A J Pharmacol Exp Ther; 2020 Mar; 372(3):331-338. PubMed ID: 31871305 [TBL] [Abstract][Full Text] [Related]
16. Covalent and non-covalent binding free energy calculations for peptidomimetic inhibitors of SARS-CoV-2 main protease. Awoonor-Williams E; Abu-Saleh AAA Phys Chem Chem Phys; 2021 Mar; 23(11):6746-6757. PubMed ID: 33711090 [TBL] [Abstract][Full Text] [Related]
17. BTK-inhibitor drug covalent binding to lysine in human serum albumin using LC-MS/MS. Muste C; Gu C Drug Metab Pharmacokinet; 2022 Feb; 42():100433. PubMed ID: 34896750 [TBL] [Abstract][Full Text] [Related]
18. Discovery of 5-Phenoxy-2-aminopyridine Derivatives as Potent and Selective Irreversible Inhibitors of Bruton's Tyrosine Kinase. Lee E; Cho H; Lee DK; Ha J; Choi BJ; Jeong JH; Ryu JH; Kang JS; Jeon R Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33126415 [TBL] [Abstract][Full Text] [Related]
19. Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition. Liclican A; Serafini L; Xing W; Czerwieniec G; Steiner B; Wang T; Brendza KM; Lutz JD; Keegan KS; Ray AS; Schultz BE; Sakowicz R; Feng JY Biochim Biophys Acta Gen Subj; 2020 Apr; 1864(4):129531. PubMed ID: 31953125 [TBL] [Abstract][Full Text] [Related]
20. Can Relative Binding Free Energy Predict Selectivity of Reversible Covalent Inhibitors? Chatterjee P; Botello-Smith WM; Zhang H; Qian L; Alsamarah A; Kent D; Lacroix JJ; Baudry M; Luo Y J Am Chem Soc; 2017 Dec; 139(49):17945-17952. PubMed ID: 29124934 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]